Leo Kim
Massachusetts Eye and Ear
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Leo Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06425419 · The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative VitreoretinopathyMassachusetts Eye and Ear Infirmary · not yet recruiting · Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment · principal investigator
- Ph1/Ph2NCT06033703 · Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal DetachmentMassachusetts Eye and Ear Infirmary · recruiting · Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of Runx1 in Pathologic Ocular AngiogenesisR01EY027739 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · fiscal years 2018 to 2022 · $502,164 awarded in 2022Same name and institution; not confirmed by an ID
- Vasculogenesis in Thyroid Eye DiseaseR21EY027061 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · fiscal years 2016 to 2017 · $246,250 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:26 UTC. The ranking covers the 200 most relevant of 136 PubMed records, and a shared surname and initials can bring in a namesake. All 136 on PubMed
- Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.J Clin Oncol · 20091,281 citationsRCR 31.5
- 905 citationsRCR 24.1
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med · 2018426 citationsRCR 14.6
- 417 citationsRCR 37.4
- 382 citationsRCR 8.7
- A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.Am J Hum Genet · 2001323 citationsRCR 7.8
- Ten year follow-up of healthy children who received one or two injections of varicella vaccine.Pediatr Infect Dis J · 2004301 citationsRCR 8.0
- 299 citationsRCR 9.3
- A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.Clin Cancer Res · 2019243 citationsRCR 8.9
- 228 citationsRCR 6.3